Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVax

Next Previous
X
Search
Drug Profile

B7-2/GM-CSF cancer gene therapy - Radient/Jaiva/NuVax

Alternative Names: CIT; Combination Immunogene Therapy

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Radient Pharmaceuticals Corporation
  • Class Cancer vaccines; Cytokine genes; Gene therapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in Canada (Parenteral, Injection)
  • 07 Dec 2010 Radient Pharmaceuticals forms new subsidiary NuVax Therapeutics, which will further develop this programme
  • 07 Apr 2010 Combination Immunogene Therapy is in active development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top